** Shares of Emergent BioSolutions rise 12.6% to $6.88 premarket
** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines
** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln
** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus
** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders
** Up to last close, stock more than doubled YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。